6,317 reports of this reaction
1.7% of all Otezla reports
#11 most reported adverse reaction
ARTHRALGIA is the #11 most commonly reported adverse reaction for Otezla, manufactured by Amgen, Inc. There are 6,317 FDA adverse event reports linking Otezla to ARTHRALGIA. This represents approximately 1.7% of all 377,221 adverse event reports for this drug.
Patients taking Otezla who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for Otezla, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for Otezla:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 6,317 FDA reports for Otezla. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 1.7% of all adverse event reports for Otezla, making it a notable side effect.
If you experience arthralgia while taking Otezla, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.